Esri and WorldPop Partner to Bring Updated Demographic Data to Policy Makers
18.12.2021 00:00:00 EET | Business Wire | Press release
The global population grew by almost two billion people during the last 20 years—nearly 30 percent. Such growth is not evenly distributed over time or across space: the extremes include Qatar growing by 400 percent and Lithuania losing 25 percent. And even within countries, the rate of growth varies. To support the need for up-to-date population data that reflects these shifts, WorldPop and Esri, the global leader in location intelligence, have partnered to include WorldPop's 1-km annual gridded demographic datasets in ArcGIS Living Atlas of the World. The data covers 241 countries, territories, and dependencies for the 2000–2020 period.
"These datasets are critical for measuring and monitoring the accompanying sociodemographic changes over time and properly informing and supporting environmental, health, and development applications at local, subnational, national, and regional levels," said Professor Andrew Tatem, Director of WorldPop at the University of Southampton. "In this context, comparable, multitemporal, and spatially explicit detailed population distribution datasets are a fundamental prerequisite for communicating the impacts of population growth."
ArcGIS Living Atlas of the World is Esri's evolving collection of ready-to-use and up-to-date authoritative content in the form of maps, apps, and data layers—all accessible via a web browser and most Esri products.
"Having the WorldPop 1-km gridded demographic datasets available as imagery layers in ArcGIS Living Atlas of the World provides unprecedented convenience to query and analyze population anywhere on Earth," said Charlie Frye, Esri chief cartographer. "That these datasets no longer need to be downloaded or preassembled prior to use will result in substantial time and cost savings for any organization needing to understand recent population changes."
Queries can include the entire 21-year history of population changes for any group, including births and five-year age cohorts. The results of these queries can be spatiotemporally analyzed using Esri's ArcGIS software to find patterns. Multitemporal datasets depict grid cell level spatial distribution of total population, age, and sex cohorts and population density.
"The age and sex gridded datasets provide invaluable information about the spatial and temporal distribution of specific demographic groups, such as children, seniors, and women of childbearing age, which are well-known to be more vulnerable than others, and thus should be explicitly considered in decision- and policy-making processes," said Dr. Alessandro Sorichetta, Associate Professor in Applied Geospatial Research at WorldPop.
The 1-km raster layers, curated by the WorldPop Spatial Data Infrastructure Team led by Dr Maksym Bondarenko, are available in ArcGIS Living Atlas of the World for population per grid cell, population density per grid cell, and population by age and sex per grid cell.
To learn more about ArcGIS Living Atlas of the World and other Esri population data layers, please visit go.esri.com/livingatlas.
About WorldPop
WorldPop, initiated in October 2013 at the University of Southampton, develops methods and applications to produce open and high-resolution geospatial datasets on population distribution, demographics, and dynamics, with a focus mainly on low- and middle-income countries, to support development, disaster-response, and health applications. WorldPop research activities are designed with full open access and operational application in mind, using transparent, fully documented and peer-reviewed methods, to produce easily updatable outputs with accompanying metadata and, where possible, measures of uncertainty. WorldPop's work contributes to and benefits from direct engagement with multiple national statistical offices, national and international agencies, universities, research centers, and large international humanitarian donors, producing rapid and strong impacts from its research. WorldPop's population datasets and analyses inform several regional and global flagship reports and are the default geospatial demographic datasets used by many governments, international organizations, UN agencies, and private companies around the World. To learn more, visit our website and/or follow us on Twitter.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005617/en/
Contact information
Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email: jpruchniewski@esri.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
